Middle East And Africa Glucagon Like Peptide 1 Agonists Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The Middle East and Africa GLP-1 receptor agonist market encompasses medications that mimic the GLP-1 hormone to treat type 2 diabetes and, increasingly, obesity and weight management. These treatments have gained prominence as effective options for metabolic diseases, with the regional market valued at approximately $1.1 billion in 2025. While the market has experienced limited recent growth, it is positioned for substantial expansion as healthcare systems develop and disease prevalence rises across the region.

• •Market valued at approximately $1.1 billion in 2025 across Middle East and Africa region
• •GLP-1 agonists treat type 2 diabetes and are increasingly used for weight management
• •Drug formulations include both injectable and emerging oral options

Rising prevalence of type 2 diabetes and obesity across the Middle East and Africa is the primary driver of market expansion. The region has some of the highest obesity rates globally, particularly in Gulf Cooperation Council countries, creating substantial demand for effective treatments. Healthcare infrastructure improvements, especially in countries like Saudi Arabia, are increasing patient access to these advanced medications.

• •Increasing obesity and diabetes rates driving demand for metabolic disease treatments
• •Multi-indication adoption expanding use from diabetes into weight management
• •Healthcare infrastructure development improving patient access and treatment availability

Semaglutide currently represents the largest product segment in the market, while tirzepatide is emerging as the fastest-growing segment. Saudi Arabia leads regional growth with the highest compound annual growth rate among Middle Eastern markets. The Gulf Cooperation Council countries represent the most developed market segment due to higher healthcare spending and greater access to advanced treatments.

• •Semaglutide is the dominant product segment, with tirzepatide showing fastest growth
• •Saudi Arabia leads regional growth with expanding healthcare infrastructure
• •GCC countries represent the largest market share due to higher treatment accessibility

What are the recent trends and outlook?

The market is expected to see substantial growth over the coming years as GLP-1 agonists become more widely adopted across additional indications and patient populations. Oral formulations are emerging as a key trend that could expand patient accessibility and convenience compared to injectable options. Continued investment in healthcare infrastructure and rising disease awareness across the region suggest strong long-term potential for market expansion.

• •Oral GLP-1 formulations emerging to improve patient convenience and accessibility
• •Multi-indication approvals expanding addressable market beyond diabetes
• •Long-term growth supported by rising disease prevalence and healthcare investments